Effects of a monoclonal anti-αvβ3 integrin antibody on blood vessels—A pharmacodynamic study

SummaryPurpose: The integrin αvβ3 is an adhesion molecule expressed by proliferating endothelial cells and antibodies blocking this integrin inhibit angiogenesis in preclinical models. MEDI-522 is a second generation humanized anti-αvβ3 antibody designed for antiangiogenic therapy. The purpose of this study was to examine potential effects of this agent on blood vessels. Experimental design: In a phase I dose escalation study, MEDI-522 was administered by weekly infusions to 25 adult patients with advanced solid organ malignancies. As a surrogate angiogenesis assay, a wound was created by punch biopsy of the arm skin. This wound site was re-biopsied after a 7-day interval. Dual-label immunofluorescence experiments followed by computer-assisted image analysis were conducted to analyze the vasculature. Results: Sequential pretreatment and 4-week treatment skin biopsy pairs were available on 4 patients, who had received 6 or 10 mg/kg of MEDI-522. MEDI-522 was detected in the dermal blood vessels as well as the dermal interstitium both in intact and wounded skin sites following treatment. No statistically significant difference was found between pretreatment and treatment samples of skin for vascular area, endothelial cell proliferation and apoptosis, or β3 integrin levels. Phosphorylated focal adhesion kinase (pFAK) was significantly diminished in skin wound vessels during MEDI-522 treatment compared to the pretreatment samples. Conclusions: MEDI-522 was detectable both in quiescent and in angiogenically active skin blood vessels as well as in the dermal interstitial space. The levels of pFAK were reduced during MEDI-522 treatment, suggesting a modulating effect on this signaling molecule.

[1]  D. Cheresh,et al.  Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. , 1994, Cell.

[2]  D. Cheresh,et al.  Integrin α v β 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels , 1994, Cell.

[3]  D. Cheresh,et al.  Requirement of vascular integrin alpha v beta 3 for angiogenesis. , 1994, Science.

[4]  S. Aizawa,et al.  Reduced cell motility and enhanced focal adhesion contact formation in cells from FAK-deficient mice , 1995, Nature.

[5]  F. Sarkar,et al.  Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. , 1995, The Journal of clinical investigation.

[6]  M. Hensler,et al.  Stepwise in vitro affinity maturation of Vitaxin, an αvβ3-specific humanized mAb , 1998 .

[7]  R. Hynes,et al.  Extensive Vasculogenesis, Angiogenesis, and Organogenesis Precede Lethality in Mice Lacking All αv Integrins , 1998, Cell.

[8]  M. Hensler,et al.  Stepwise in vitro affinity maturation of Vitaxin, an alphav beta3-specific humanized mAb. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[9]  R. Hynes,et al.  Beta3-integrin-deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival. , 1999, The Journal of clinical investigation.

[10]  M. Schwartz,et al.  Focal Adhesion Kinase Mediates the Integrin Signaling Requirement for Growth Factor Activation of Map Kinase , 1999, The Journal of cell biology.

[11]  A. Aplin,et al.  Anchorage-dependent Regulation of the Mitogen-activated Protein Kinase Cascade by Growth Factors Is Supported by a Variety of Integrin α Chains* , 1999, The Journal of Biological Chemistry.

[12]  E. Fishman,et al.  Application of CT in the investigation of angiogenesis in oncology. , 2000, Academic radiology.

[13]  C. Damsky,et al.  FAK integrates growth-factor and integrin signals to promote cell migration , 2000, Nature Cell Biology.

[14]  T. N. Campbell,et al.  Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[15]  G. Wilding,et al.  Tissue examination to monitor antiangiogenic therapy: a phase I clinical trial with endostatin. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[16]  R. Benjamin,et al.  Pilot study of vitaxin—an angiogenesis inhibitor—in patients with advanced leiomyosarcomas , 2001, Cancer.

[17]  D. Taverna,et al.  Enhanced pathological angiogenesis in mice lacking beta3 integrin or beta3 and beta5 integrins. , 2002, Nature medicine.

[18]  P. Carmeliet.  Integrin indecision , 2002, Nature Medicine.

[19]  D. Stupack,et al.  Integrin-mediated death: An explanation of the integrin-knockout phenotype? , 2002, Nature Medicine.

[20]  R. Hynes.  A reevaluation of integrins as regulators of angiogenesis , 2002, Nature Medicine.

[21]  C. Damsky,et al.  Focal Adhesion Kinase Is Required for Blood Vessel Morphogenesis , 2003, Circulation research.

[22]  Bruce Klitzman,et al.  Reduction of wound angiogenesis in patients treated with BMS-275291, a broad spectrum matrix metalloproteinase inhibitor. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[23]  J. Parsons,et al.  Focal adhesion kinase: the first ten years , 2003, Journal of Cell Science.

[24]  Jens Eickhoff,et al.  Phase I Trial of a Monoclonal Antibody Specific for αvβ3 Integrin (MEDI-522) in Patients with Advanced Malignancies, Including an Assessment of Effect on Tumor Perfusion , 2005, Clinical Cancer Research.

[25]  D. A. Hanson,et al.  Focal adhesion kinase: in command and control of cell motility , 2005, Nature Reviews Molecular Cell Biology.

[26]  R. Flavell,et al.  Conditional knockout of focal adhesion kinase in endothelial cells reveals its role in angiogenesis and vascular development in late embryogenesis , 2005, The Journal of cell biology.